Application of bile acids in drug formulation and delivery

Frontiers in Life Science

Volumn 7, Issue 3-4, 2013, Pages 112-122

  Stojančević, Maja ^a   Pavlović, Nebojša ^a   Goločorbin Kon, Svetlana ^a   Mikov, Momir ^a,b  

^a UNIVERSITY OF NOVI SAD   (Serbia)

^b CURTIN UNIVERSITY   (Australia)

Author keywords

absorption enhancers; bile acids; drug bioavailability; drug delivery; pharmaceutical formulations

Indexed keywords

EID: 84899569535     PISSN: 21553769     EISSN: 21553777     Source Type: Journal    
DOI: 10.1080/21553769.2013.879925     Document Type: Article

References (91)

1. Al-Salami H, Butt G, Tucker I, Mikov M. 2008. Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide in vitro in healthy and diabetic rats treated with probiotics. Methods Find Exp Clin Pharmacol. 30:107-113. doi: 10.1358/mf.2008.30.2.1159652
2. Begley M, Gahan CGM, Hill C. 2005. The interaction between bacteria and bile. FEMS Microbiol Rev. 29:625-651. doi: 10.1016/j.femsre.2004.09.003
3. Bitounis D, Fanciullino R, Iliadis A, Ciccolini J. 2012. Optimizing druggability through liposomal formulations: New approaches to an old concept. ISRN Pharm. 2012: 738432.
4. de Boer AG, Moolenaar F, de Leede LGJ, Breimer DD. 1982. Rectal drug administration: clinical pharmacokinetic considerations. 7:285-311.
5. Bowe CL, Mokhtarzadeh L, Venkatesan P, Babu S, Axelrod HR, Sofia MJ, Kakarla R, Chan TY, Kim JS, Lee HJ, et al. 1997. Design of compounds that increase the absorption of polar molecules. Proc Natl Acad Sci USA. 94:12218-12223. doi: 10.1073/pnas.94.22.12218
6. Carey MC, Small DM. 1972. Micelle formation by bile salts: Physical-chemical and Thermodynamic Considerations. Arch Intern Med. 130:506-527. doi: 10.1001/archinte.1972.03650040040005
7. Chavanpatil MD, Vavia PR. 2004. The influence of absorption enhancers on nasal absorption of acyclovir. Eur J Pharm Biopharm. 57:483-487. doi: 10.1016/j.ejpb.2004.01.001
8. Chen G, Fawcett JP, Mikov M, Tucker IG. 2009a. Monoketocholate can decrease transcellular permeation of methotrexate across Caco-2 cell monolayers and reduce its intestinal absorption in rat. J Pharm Pharmacol. 61(7):953-959. doi: 10.1211/jpp.61.07.0016
9. Chen G, Yang L, Zhang H, Tucker IG, Fawcett JP. 2012. Effect of ketocholate derivatives on methotrexate uptake in Caco-2 cell monolayers. Int J Pharm. 433:89-93. doi: 10.1016/j.ijpharm.2012.04.077
10. Chen Y, Lu Y, Chen J, Lai J, Sun J, Hu F, Wu W. 2009b. Enhanced bioavailability of the poorly water-soluble drug fenofibrate by using liposomes containing a bile salt. Int J Pharm. 376:153-160. doi: 10.1016/j.ijpharm.2009.04.022
11. Chun IK. 2009. Dissolution and duodenal permeation characteristics of lovastatin from bile salt solid dispersions: role of critical micelle concentration. J Kor Pharm Sci. 39:97-106.
12. Coyne CB, Ribeiro CM, Boucher RC, Johnson LG. 2003. Acute mechanism of medium chain fatty acid-induced enhancement of airway epithelial permeability. J Pharmacol Exp Ther. 305:440-450. doi: 10.1124/jpet.102.047654
13. Criado JJ, Herrera MC, Palomero MF, Medarde M, Rodriguez E, Marin JJ. 1997. Synthesis and characterization of a new bile acid and platinum (II) complex with cytostatic activity. J Lipid Res. 38(5):1022-1032. doi:
14. Darkoh C, Lichtenberger LM, Ajami N, Dial EJ, Jiang ZD, DuPont HL. 2010. Bile acids improve the antimicrobial effect of rifaximin. Antimicrob Agents Chemother. 54:3618-3624. doi: 10.1128/AAC.00161-10
15. Donovan MD, Flynn GL, Amidon GL. 1990. The molecular weight dependence of nasal absorption: the effect of absorption enhancers. Pharm Res. 7:808-815. doi: 10.1023/A:1015904730599
16. Fetih G, Ibrahim MA, Amin MA. 2011. Design and characterization of transdermal films containing ketorolac tromethamine. Int J Chem Tech Res. 3:449-458.
17. Fujii Y, Kanamaru T, Kikuchi H, Nakagami H, Yamashita S, Akashi M, Sakuma S. 2011. Improvement of low bioavailability of a novel factor Xa inhibitor through formulation of cationic additives in its oral dosage form. Int J Pharm. 421:244-251. doi: 10.1016/j.ijpharm.2011.09.046
18. Garidel P, Hildebrand A, Knauf K, Blume A. 2007. Membranolytic activity of bile salts: influence of biological membrane properties and composition. Molecules. 12:2292-2326. doi: 10.3390/12102292
19. Goločorbin-Kon S, Mikov M, Arafat M, Lepojevic Z, Mikov I, Sahman-Zaimovic M, Tomic Z. 2009. Cefotaxime pharmacokinetics after oral application in the form of 3alpha,7alpha-dihydroxy-12-keto-5beta-cholanate microvesicles in rat. Eur J Drug Metab Pharmacokinet. 34:31-36. doi: 10.1007/BF03191381
20. Gordon GS, Moses AC, Silver RD, Flier JS, Carey MC. 1985. Nasal absorption of insulin: enhancement by hydrophobic bile salts. Proc Natl Acad Sci USA. 82:7419-7423. doi: 10.1073/pnas.82.21.7419
21. Gregoriadis G, Florence AT, Patel HM. 2000. Liposomes in Drug Delivery. UK: Hardwood Academic Publishers.
22. Guan P, Lu Y, Qi J, Niu M, Lian R, Hu F, Wu W. 2011. Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt. Int J Nanomedicine. 6:965-674.
23. Hirai S, Yashiki T, Mima H. 1981. Effect of surfactants on the nasal absorption of insulin in rats. Int J Pharm. 9:165-172. doi: 10.1016/0378-5173(81)90009-0
24. Hofmann AF. 2009. Bile acids: trying to understand their chemistry and biology with the hope of helping patients. Hepatology. 49(5):1403-1418. doi: 10.1002/hep.22789
25. van Hoogdalem EJ, Heijligers-Feijen CD, Mathôt RA, Wackwitz AT, van Bree JB, Verhoef JC, de Boer AG, Breimer DD. 1989. Rectal absorption enhancement of cefoxitin and desglycinamide arginine vasopressin by sodium tauro-24,25-dihydrofusidate in conscious rats. J Pharmacol Exp Ther. 251:741-744.
26. Hussain A, Arnold JJ, Khan MA, Ahsan F. 2004. Absorption enhancers in pulmonary protein delivery. J Control Release. 94:15-24. doi: 10.1016/j.jconrel.2003.10.001
27. Ikeda K, Murata K, Kobayashi M, Noda K. 1992. Enhancement of bioavailability of dopamine via nasal route in beagle dogs. Chem Pharm Bull. 40:2155-2158. doi: 10.1248/cpb.40.2155
28. Ingels F, Beck B, Oth M, Augustijns P. 2004. Effect of simulated intestinal fluid on drug permeability estimation across Caco-2 monolayers. Int J Pharm. 274:221-232. doi: 10.1016/j.ijpharm.2004.01.014
29. Johansson F, Hjertberg E, Eirefelt S, Tronde A, Hultkvist Bengtsson U. 2002. Mechanisms for absorption enhancement of inhaled insulin by sodium taurocholate. Eur J Pharm Sci. 17:63-71. doi: 10.1016/S0928-0987(02)00133-1
30. Kim K, Yoon I, Chun I, Lee N, Kim T, Gwak HS. 2011. Effects of bile salts on the lovastatin pharmacokinetics following oral administration to rats. Drug Deliv. 18:79-83. doi: 10.3109/10717544.2010.512024
31. Kobayashi S, Kondo S, Juni K. 1996. Pulmonary delivery of salmon calcitonin dry powders containing absorption enhancers in rats. Pharm Res. 13:80-83. doi: 10.1023/A:1016081301369
32. Kolhatkar V, Polli JE. 2012. Structural requirements of bile acid transporters: C-3 and C-7 modifications of steroidal hydroxyl groups. Eur J Pharm Sci. 46(1-2):86-99. doi: 10.1016/j.ejps.2012.02.012
33. Kramer W. 2011. Transporters, Trojan horses and therapeutics: suitability of bile acid and peptide transporters for drug delivery. Biol Chem. 392(1-2):77-94. doi: 10.1515/bc.2011.017
34. Kramer W, Wess G, Enhsen A, Falk E, Hoffmann A, Neckermann G, Schubert G, Urmann M. 1997. Modified bile acids as carriers for peptides and drugs. J Control Release. 46(1-2):17-30. doi: 10.1016/S0168-3659(96)01599-4
35. Kuhajda K, Kevrešan S, Mikov M, Sabo A, Miljković D. 1997. 3-dihydroxy-12-oxo-5β-cholanate as enhancer of insulin nasal absorption in rats. Arch Toxicol Kinet Xenobiot Metabol. 5:359-361.
36. Lee DY, Lee J, Lee S, Kim SK, Byun Y. 2007. Liphophilic complexation of heparin based on bile acid for oral delivery. J Control Release. 123(1):39-45. doi: 10.1016/j.jconrel.2007.07.013
37. Lee S, Kim K, Kumar TS, Lee J, Kim SK, Lee DY, Lee YK, Byun Y. 2005. Synthesis and biological properties of insulin-deoxycholic acid chemical conjugates. Bioconjug Chem. 16(3):615-620. doi: 10.1021/bc049871e
38. Le Ferrec E, Chesne C, Artusson P, Brayden D, Fabre G, Gires P, Guillou F, Rousset M, Rubas W, Scarino ML. 2001. In vitro models of the intestinal barrier. The report and recommendations of ECVAM workshop 46. European centre for the validation of alternative methods. Altern Lab Anim. 29:649-668.
39. Longenecker JP, Moses AC, Flier JS, Silver RD, Carey MC, Dubovi EJ. 1987. Effects of sodium taurodihydrofusidate on nasal absorption of insulin in sheep. J Pharm Sci. 76(5): 351-355. doi: 10.1002/jps.2600760502
40. Maestrelli F, Cirri M, Mennini N, Zerrouk N, Mura P. 2011. Improvement of oxaprozin solubility and permeability by the combined use of cyclodextrin, chitosan, and bile components. Eur J Pharm Biopharm. 78:385-393. doi: 10.1016/j.ejpb.2011.03.012
41. Maitani Y, Asano S, Takahashi S, Nakagaki M, Nagai T. 1992. Permeability of insulin entrapped in liposome through the nasal mucosa of rabbits. Chem Pharm Bull. 40:1569-1572. doi: 10.1248/cpb.40.1569
42. Mann JFS, Scales HE, Shakir E, Alexander J, Carter KC, Mullen AB, Ferro VA. 2006. Oral delivery of tetanus toxoid using vesicles containing bile salts (bilosomes) induces significant systemic and mucosal immunity. Methods. 38(2):90-95. doi: 10.1016/j.ymeth.2005.11.002
43. Martin GP, El-Hariri LM, Marriott C. 1992. Bile salt- and lysophosphatidyl choline-induced membrane damage in human erythrocytes. J Pharm Phramacol. 44:646-660. doi: 10.1111/j.2042-7158.1992.tb05486.x
44. Meaney CM, O'Driscoll CM. 2000. A comparison of the permeation enhancement potential of simple bile salt and mixed bile salt: fatty acid micellar systems using the CaCo-2 cell culture model. Int J Pharm. 207:21-30. doi: 10.1016/S0378-5173(00)00526-3
45. Michael S, Thöle M, Dillmann R, Fahr A, Drewe J, Fricker G. 2000. Improvement of intestinal peptide absorption by a synthetic bile acid derivative, cholylsarcosine. Eur J Pharm Sci. 10:133-140. doi: 10.1016/S0928-0987(99)00093-7
46. Mikov M, Fawcett JP. 2007. Bile acids: Chemistry, biosynthesis, analysis, chemical and metabolic transformations and pharmacology. Geneva, Switzerland: Mediset Publisher.
47. Mikov M, Kevrešan S, Kuhajda K, Jakovljević V, Vasović V. 2004. 3-dihydroxy-12-oxo-5β-cholanate as blood-brain barrier permeator. Pol J Pharmacol. 56:367-371. doi: 10.1211/0022357022782
48. Mikov M, Raskovic A, Jakovljevic E, Dudvarski D, Fawcett JP. 2005. Influnce of the bile salt sodium dihydrooxy-12-oxo-5β- cholanate on ampicillin pharmacokinetics in rats. Asian Journal of Drug Metabolism and Pharmacokinetics. 5:197-200.
49. Misra A, Ganesh S, Shahiwala A, Shah SP. 2003. Drug delivery to the central nervous system: a review. J Pharm Pharmaceut Sci. 6:252-273.
50. Mithani SD, Bakatselou V, TenHoor CN, Dressman JB. 1996. Estimation of the increase in solubility of drugs as a function of bile salt concentration. Pharm Res. 13:163-167. doi: 10.1023/A:1016062224568
51. Miyake M, Minami T, Hirota M, Toguchi H, Odomi M, Ogawara K, Higaki K, Kimura T. 2006. Novel oral formulation safely improving intestinal absorption of poorly absorbable drugs: utilization of polyamines and bile acids. J Control Release. 111:27-34. doi: 10.1016/j.jconrel.2005.11.010
52. Moghimipour E, Sajjadi Tabassi SA, Kouchak M, Varghaei H. 2012. Combination strategies for enhancing transdermal absorption of theophylline through shed snake skin. Asian J Pharm Clin Res. 5:30-34.
53. Monte MJ, Marin JJ, Antelo A, Vazquez-Tato J. 2009. Bile acids: chemistry, physiology, and pathophysiology. World J Gastroenterol. 15:804-816. doi: 10.3748/wjg.15.804
54. Moses AC, Gordon GS, Carey MC, Flier JS. 1983. Insulin administration intranasally as an insulin-bile salt aerosol: Effectiveness and Reproducibility in Normal and Diabetic Subjects. Diabetes. 32:1040-1047. doi: 10.2337/diab.32.11.1040
55. Mrestani Y, Bretschneider B, Härtl A, Neubert RHH. 2003. In vitro and in vivo studies of cefpirom using bile salts as absorption enhancers. J Pharm Pharmacol. 55:1601-1606. doi: 10.1211/0022357022214
56. Mukaizawa F, Taniguchi K, Miyake M, Ogawara K, Odomi M, Higaki K, Kimura T. 2009. Novel oral absorption system containing polyamines and bile salts enhances drug transport via both transcellular and paracellular pathways across Caco-2 cell monolayers. Int J Pharm. 367:103-108. doi: 10.1016/j.ijpharm.2008.09.027
57. Murakami T, Sasaki Y, Yamajo R, Yata N. 1984. Effect of bile salts on the rectal absorption of sodium ampicillin in rats. Chem Pharm Bull. 32:1948-1955. doi: 10.1248/cpb.32.1948
58. Nanjwade BK, Patel DJ, Udhani RA, Manvi FV. 2011. Functions of lipids for enhancement of oral bioavailability of poorly water-soluble drugs. Sci Pharm. 79:705-727. doi: 10.3797/scipharm.1105-09
59. Niu M, Lu Y, Hovgaard L, Guan P, Tan Y, Lian R, Qi J, Wu W. 2012. Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: the effect of cholate type, particle size and administered dose. Eur J Pharm Biopharm. 81(2):265-272. doi: 10.1016/j.ejpb.2012.02.009
60. Noble S, Markham A. 1995. Cyclosporine: a review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral®). Drugs. 50:924-941. doi: 10.2165/00003495-199550050-00009
61. OReilly JR, Corrigan OI, O'Driscoll CM. 1994. The effect of mixed micellar systems, bile-salt/fatty-acids, on the solubility and intestinal-absorption of clofazimine (B663) in the anesthetized rat. Int Journ Pharm. 109:147-154. doi: 10.1016/0378-5173(94)90142-2
62. Palin KJ. 1985. Lipids and oral drug delivery. Pharm Int. 6: 272-275.
63. Parmentier J, Becker MM, Heintz U, Fricker G. 2011. Stability of liposomes containing bio-enhancers and tetraether lipids in simulated gastro-intestinal fluids. Int J Pharm. 405(1-2): 210-217. doi: 10.1016/j.ijpharm.2010.12.005
64. Pavlović N, Stankov K, Mikov M. 2012. Probiotics-interactions with bile acids and impact on cholesterol metabolism. Appl Biochem Biotechnol. 168(7):1880-1895. doi: 10.1007/s12010-012-9904-4
65. Pilcer G, Amighi K. 2010. Formulation strategy and use of excipients in pulmonary drug delivery. Int Journ Pharm. 392:1-19. doi: 10.1016/j.ijpharm.2010.03.017
66. Poelma FG, Breäs R, Tukker JJ. 1990. Intestinal absorption of drugs. III. The influence of taurocholate on the disappearance kinetics of hydrophilic and lipophilic drugs from the small intestine of the rat. Pharm Res. 7:392-397. doi: 10.1023/A:1015827624296
67. Poša M, Kevrešan S, Mikov M, Ćirin-Novta V, Kuhajda K. 2007. Effect of cholic acid and its keto derivatives on the analgesic action of lidocaine and associated biochemical parameters in rats. Eur J Drug Metab Pharmacokinet. 32:109-117. doi: 10.1007/BF03190999
68. Poša MM, Kuhajda KN. 2010. Influence of bile acids on the adsorption of lidocaine and verapamil in an in vitro experiment. J Serb Chem Soc. 75:433-440. doi: 10.2298/JSC080810029P
69. Rais R, Fletcher S, Polli JE. 2011. Synthesis and in vitro evaluation of gabapentin prodrugs that target the human apical sodium-dependent bile acid transporter (hASBT). J Pharm Sci. 100(3):1184-1195. doi: 10.1002/jps.22332
70. Roberto M, Ornella F, Yukkio K, Zenaida G, Paolo G, Irwin MA. 1994. Bile acid inhibition of P-glycoprotein-mediated transport in multidrug-resistant cells and rat liver canalicular membrane vesicles. Hepatology. 20:170-176.
71. Rupenthal ID, Alany RG. 2008. Ocular drug delivery. In: Shayne CG, editor. Pharmaceutical manufacturing handbook: Production and processes. New Jersey: John Wiley and Sons; p. 729-769.
72. Saettone MF, Chetoni P, Cerbai R, Mazzanti G, Braghiroli L. 1996. Evaluation of ocular permeation enhancers: in vitro effects on corneal transport of four β-blockers, and in vitro/in vivo toxic activity. Int Journ Pharm. 142:103-113. doi: 10.1016/0378-5173(96)04663-7
73. Sasaki H, Yamamura K, Tei C, Nishida K, Nakamura J. 1995. Ocular permeability of FITC-dextran with absorption promoter for ocular delivery of peptide drug. J Drug Target. 3(2):129-135. doi: 10.3109/10611869509059212
74. Senior K. 2001. Bilosomes: the answer to oral vaccine delivery? Drug Discov Today. 6(20):1031-1032. doi: 10.1016/S1359-6446(01)02010-4
75. Shukla A, Khatri K, Gupta PN, Goyal AK, Mehta A, Vyas SP. 2008. Oral immunization against hepatitis B using bile salt stabilized vesicles (bilosomes). J Pharm Pharm Sci. 11(1):59-66.
76. Song KH, Chung SJ, Shi CK. 2005. Enhanced intestinal absorption of salmon calcitonin (sCT) from proliposomes containing bile salts. J Control Release. 106:298-308. doi: 10.1016/j.jconrel.2005.05.016
77. Stanimirov B, Stankov K, Mikov M. 2012. Pleiotropic functions of bile acids mediated by the farnesoid X receptor. Acta Gastroenterol Belg. 75(4):389-398.
78. Stojančević M, Bojić G, Salami HA, Mikov M. 2013. The influence of intestinal tract and probiotics on the fate of orally administered drugs. Curr Issues Mol Biol. 16(2):55-68.
79. Stojančević M, Stankov K, Mikov M. 2012. The impact of farnesoid X receptor activation on intestinal permeability in inflammatory bowel disease. Can J Gastroenterol. 26(9):631-637.
80. Sugioka H, Moroi Y. 1998. Micelle formation of sodium cholate and solubilization into the micelle. Biochim Biophys Acta. 1394:99-110. doi: 10.1016/S0005-2760(98)00090-3
81. Tolle-Sander S, Lentz KA, Maeda DY, Coop A, Polli JE. 2004. Increased acyclovir oral bioavailability via a bile acid conjugate. Mol Pharm. 1(1):40-48. doi: 10.1021/mp034010t
82. Uhumwangho MU, Okor RS. 2005. Current trends in the production and biomedical applications of liposomes: a review. J Medicine and Biomedical Research. 4:9-21.
83. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. 2002. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 45:2615-2623. doi: 10.1021/jm020017n
84. Verzele D, Figaroli S, Madder A. 2011. Shortcut access to peptidosteroid conjugates: building blocks for solid-phase bile acid scaffold decoration by convergent ligation. Molecules. 16(12):10168-10186. doi: 10.3390/molecules161210168
85. Wu T, Guo JX, Ping QN, Jin FY, Sun XW. 2001. Transdermal delivery of cyclosporin A solubilized in mixed micelles through mice skin. Yao Xue Xue Bao. 36:381-385.
86. Wüstner D, Herrmann A, Müller P. 2000. Head group-independent interaction of phospholipids with bile salts. A fluorescence and EPR study. J Lipid Res. 41(3): 395-404.
87. Yamamoto A, Hayakawa E, Kato Y, Nishiura A, Lee VH. 1992. A mechanistic study on enhancement of rectal permeability to insulin in albino rabbits. J Pharmacol Exp Ther. 263:25-31.
88. Yamamoto A, Luo A, Dodda-Kashi S, Lee V. 1989. The ocular route for systemic insulin delivery in the albino rabbit. J Pharmacol Exp Ther. 249:249-255.
89. Yang L, Fawcett JP, Østergaard J, Zhang H, Tucker IG. 2012. Mechanistic studies of the effect of bile salts on rhodamine 123 uptake into RBE4 cells. Mol Pharm. 9:29-36. doi: 10.1021/mp200201y
90. Yang L, Zhang H, Fawcett JP, Mikov M, Tucker IG. 2011. Effect of bile salts on the transport of morphine-6-glucuronide in rat brain endothelial cells. J Pharm Sci. 100:1516-1524. doi: 10.1002/jps.22390
91. Zhang Y, Jiang XG, Yao J. 2001. Nasal absorption enhancement of insulin by sodium deoxycholate in combination with cyclodextrins. Acta Pharmacol Sin. 22:1051-1056.